Our observation might lead to a conclusion that disrupted gene expression levels, including some splicing factors’ downregulation, in BRAF-driven melanoma cells can result in unbalanced splicing machinery that provides an advantage for cancer cells under a selective pressure of vemurafenib. This evidence concerns the gene BRAF and cancer.